Netscientific Share Discussion Threads

[weatherman] 10/6/2021 19:56

I see posted already - but some useful comment from the CEO about future plans, NAV and the discount.

[the stigologist] 10/6/2021 19:06

NSCI is in serious bull mode with value inflection catalysts imminent

News due on all 3 of its big 'game changing investments'

ProAxsis - securing a global in-licence deal for a covid test AstraZeneca developed internally is an indicator these guys punch well above their weight

PDSB - After publishing incredibly exciting early Proof of Concept data in a Phase I/II cancer trial they will be hosting an Oncology R&D Day where their Partners just the US Government 'National Cancer Institute' will have 3 scientists presenting on their behalf!

Glycotest - has been very much in stealth mode but clinical trials approaching completion and gearing up for commercialisation phase (just happen to have Chinese conglomerate Fosun as 55-45 JV partner who are Pfizer/BioNTech vaccine partner in China)

I am accumulating

[4vik] 10/6/2021 17:42

Have you been offered?

[bscuit] 10/6/2021 17:26

Stepped aboard in the placing.

[saint in exile] 10/6/2021 16:32

Just convert one of the first four letters into a capital to create a link blakieboy

[blakieboy7] 10/6/2021 15:24

https://www.proactiveinvestors.co.uk/companies/news/951911/netscientific-to-raise-funds-to-accelerate-its-renaissance-951911.html

[the stigologist] 10/6/2021 15:10

Wonder if Raj Chawla bought more in the Placing

If it is same one involved with Goldcrest (trade finance to growth companies) there is some obvious expertise and synergies in a relationship

[blakieboy7] 10/6/2021 13:20

Yep it was oversubscribed

[kalkaar] 10/6/2021 13:00

so confirmed £7.7m raised

[blakieboy7] 10/6/2021 13:00

, Chief Executive Officer added: "NetScientific is well positioned to drive its growth plans, support a balanced and expanding portfolio, and pursue attractive trans-Atlantic opportunities in the healthcare and sustainability sectors in a post-COVID environment. We're delighted to welcome the support of a new institutional investor and the strong investor support in this placement provides further impetus behind our model of 'capital-light' investment combined with pro-active management and value added support to our portfolio."

[blakieboy7] 10/6/2021 12:58

TIDMNSCIRNS Number : 5243BNetScientific PLC10 June 2021THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE RESTRICTED AND ARE NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR A SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA. NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY SUCH OFFER, SOLICITATION OR COMMITMENT WHATSOEVER IN ANY OF THOSE JURISDICTIONS.NetScientific PLC("NetScientific" or the "Company")Result of Placing and Total Voting RightsNetScientific, the life sciences and sustainability technology investment and commercialisation group, is pleased to announce that it has raised gross proceeds of approximately GBP7.7 million in an oversubscribed fundraising as announced earlier today (the "Placing").A total of 5,958,123 Placing Shares in the Company have been conditionally placed by WH Ireland Limited ("WH Ireland") with new and existing investors at a price of 130 pence per share (the "Issue Price").Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM and it is anticipated that dealings in the Placing Shares will commence on AIM at 8.00 a.m. on 29 June 2021 ("Admission"). The Placing Shares will represent approximately 28.4 per cent. of the Company's issued share capital following completion of the Placing ("Enlarged Share Capital"). The Issue Price represents a discount of approximately 10.3 per cent. to the closing mid-market price of NetScientific's existing ordinary shares of 145 pence on 9 June 2021 (being the last business day prior to the announcement of the Placing earlier today).The Placing is subject to, inter alia, shareholder approval, Admission becoming effective and the Placing Agreement becoming unconditional and not being terminated in accordance with its terms.The Company expects to publish a circular in connection with the Placing, in due course, which will contain a notice convening the General Meeting in order to approve certain matters necessary to implement the Fundraising.A copy of the Circular will be made available on the Company's website https://NetScientific.co.uk/investorsDue to the unpredictability of the UK Government guidance and continuing potential health risks posed by COVID-19, it appears to the Directors that significant restrictions on personal movement may still be in place on the date of the General Meeting. Accordingly, the Company will hold the General Meeting with the minimum attendance required to form a quorum and the Directors strongly encourage all Shareholders to vote on the Resolutions by proxy or online. Any Shareholders seeking to attend the General Meeting in person will be refused entry.The actions that Shareholders should take to vote on the Resolutions will be set out in the Circular to be posted in due course, along with the recommendations of the Directors.Following Admission, the Company's issued and fully paid share capital will consist of 20,975,311 Ordinary Shares, all of which carry one voting right per share. The Company does not hold any Ordinary Shares in treasury. The figure of 20,975,311 Ordinary Shares may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.Capitalised terms used but not defined in this announcement have the meanings given to them in the Company's announcement released earlier today in respect of the Placing unless the context provides otherwise.John Clarkson, Executive Chairman, stated: "After a year of tremendous progress, with the turnaround and transformation of the business, the company is now well set for the future. We are delighted to have the support of existing shareholders and welcome new investors in this successful placing, which reinforces and further enhances the business prospects. The NetScientific board thanks everyone for their contribution to this ongoing success."Ilian Iliev , Chief Executive Officer added: "NetScientific is well positioned to drive its growth plans, support a balanced and expanding portfolio, and pursue attractive trans-Atlantic opportunities in the healthcare and sustainability sectors in a post-COVID environment. We're delighted to welcome the support of a new institutional investor and the strong investor support in this placement provides further impetus behind our model of 'capital-light' investment combined with pro-active management and value added support to our portfolio."

[kalkaar] 10/6/2021 12:51

fwiw i think they'll have secured £9-10m from investors and it'll all be sewn up by close of play

given that they were looking for less than half that initially let's hope the proceeds are employed as wisely as the investment in PDSB

focus should then quickly turn to getting the AZN deal over the line with product validation

[chesty1] 10/6/2021 12:36

Bertie AGY does look good....but so too does SAR at the mo!! Nudge Nudge!

[bertiebingo] 10/6/2021 12:35

Sorry my mistake, I thought someone said a few days ago that Glycotest is expected to list

[bertiebingo] 10/6/2021 12:29

Bought some today having watched a couple of presentations

[kalkaar] 10/6/2021 11:23

they've not stated anywhere they're letting glycotest go, so not sure where you've got that from?!

It's 40% owned by Fosun - if anyone's going to buy NSCI's majority stake in Glycotest it will be Fosun as Liver Cancer is massive in China/Asia

first they need to update the market where they're at with commercialising HCC (their liver cancer screening test) in the States

my understanding is that that'll come within next couple of months

Fosun on track to launch HCC Q1 2022 in China

[everready1] 10/6/2021 11:20

When are Glyco test results due ?

[bertiebingo] 10/6/2021 10:58

Re Glycotest IPO,have they indicated whether it's primary, secondary or both ?

[kalkaar] 10/6/2021 10:10

previous management teams at NSCI were very passive and not very driven - they did however get NSCI into glycotest which could turn out to be the jewel in the crown so not all bad..

best move by current Chairman was getting EMV Capital to effectively reverse into NSCI bringing with it all portfolio companies and a connected, talented and driven CEO.

rest is history as they say although has taken a while for market to appreciate the extent of the turnaround and company's new focus and approach..

with turnaround complete, company now motoring fast into growth phase..

[kalkaar] 10/6/2021 10:00

Stig, no, Woodford won't be involved..

a couple of specialist/boutique, aggressive "growth-biased" institutions on board though who invest in special situations

[the stigologist] 10/6/2021 09:55

IF WHIreland manage the bookbuild right there should be healthy aftermarket

Wonder if Neil Woodford may get involved

He loved this

[billthebank] 10/6/2021 09:54

So close to turning blue.Didnt expect that but when you consider

1 PLACING price puts a new base of 130
2 Co only valued at sub £30M
3 Cash held £8M
4 5.75% owned PDSB

There is no longer any downside tbh!!

Come on all those negative posters what say you now.Lets be having you!!! DON'T go all shy on us now.We need you to keep our feet on the ground!!!!

[the stigologist] 10/6/2021 09:52

The £40 potential future NAV is probably about £30 now but the £7m may accelerate how quickly we get to £30

:-D

[loafofbread] 10/6/2021 09:46

I prefer your £40 spread sheet!